I'm trying to understand who funds the CFI

[vli]

Apologies if this is in the wrong section.

I'm trying to understand the Chronic Fatigue Initiative http://cfinitiative.org/about-the-initiative/.

It says "Headquartered in New York City and funded by the Hutchins Family Foundation..."--so the whole initiative is funded by this one Family Foundation? I then tried to google this foundation. Nothing--all I could find was a lot of info about a Harvard alumnus called Glenn Hutchins. So the whole hunt (at least the Lipkin one) for pathogens is attributable to him?

http://en.wikipedia.org/wiki/Glenn_Hutchins

 

[Firestormm]

vli Yep. Well the Family Foundation at any rate. Check this one out if you haven't already, there was more written around the same time

Did you make it to London (your signature)?

 

[vli]

Wow. This is so impressive. Thanks Firestormm. Unbelievable what 1 rich family can do.

Yes I'm in Hong Kong now... it's a long story. I was in NYC last year doing Ampligen with Enlander, but I used to live in London, now I live here

 

[Simon]

Since then the Hutchins Family Foundation have out $30m into Harvard
http://news.harvard.edu/gazette/story/2012/10/a-30m-gift-to-university/

But yes, it seem Glenn Hutchins is doing a lot. What hAs impressed me about CFI is not just the cash they are committing but the way they are going about it, bring in top talent like Lipkin and Klimas,as well as tackling the problem in a comprehensive way inc epidemiology (tapping in to huge cohort studies run by Harvard), pathogens and identifying and then researching key hypotheses.

Btw, think this thread should be under General ME new.

 

[vli]

OK I'd be grateful for any of the mods moving it!!

 

[Nielk]

Carlson says the Hutchins family was interested in CFS research because it's "orphaned" compared with diseases like Parkinson's, which, like CFS, affects an estimated 1 million Americans. The family has several friends with the disease, he said.
Several features make the initiative different from previous CFS studies, Carlson says—the technology Lipkin will use, the size and careful characterization of the cohort, the investigators involved, and the business-driven approach. "I don't think anybody's ever taken as comprehensive an approach," he says. If the studies yield promising results, the family hopes that larger foundations will kick in more funding.

Very impressive.